GB9213559D0 - Vaccines - Google Patents

Vaccines

Info

Publication number
GB9213559D0
GB9213559D0 GB9213559A GB9213559A GB9213559D0 GB 9213559 D0 GB9213559 D0 GB 9213559D0 GB 9213559 A GB9213559 A GB 9213559A GB 9213559 A GB9213559 A GB 9213559A GB 9213559 D0 GB9213559 D0 GB 9213559D0
Authority
GB
United Kingdom
Prior art keywords
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9213559A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to GB9213559A priority Critical patent/GB9213559D0/en
Publication of GB9213559D0 publication Critical patent/GB9213559D0/en
Priority to NZ253137A priority patent/NZ253137A/en
Priority to SG9901248A priority patent/SG90042A1/en
Priority to EP19930912991 priority patent/EP0649470A1/en
Priority to EP96203085A priority patent/EP0761231B1/en
Priority to PCT/EP1993/001525 priority patent/WO1994000575A1/en
Priority to RU94046232A priority patent/RU2118164C1/ru
Priority to SG1996009012A priority patent/SG49909A1/en
Priority to CA 2138996 priority patent/CA2138996A1/en
Priority to JP6502006A priority patent/JPH07508648A/ja
Priority to PL93306722A priority patent/PL170980B1/pl
Priority to DK96203085T priority patent/DK0761231T3/da
Priority to AT96203085T priority patent/ATE188613T1/de
Priority to DE69313134T priority patent/DE69313134T2/de
Priority to AU43263/93A priority patent/AU661404B2/en
Priority to PT96203085T priority patent/PT761231E/pt
Priority to HU9403778A priority patent/HU219808B/hu
Priority to AU43264/93A priority patent/AU676166B2/en
Priority to SK1592-94A priority patent/SK279188B6/sk
Priority to ES96203085T priority patent/ES2143716T3/es
Priority to JP50200594A priority patent/JP3755890B2/ja
Priority to NZ253138A priority patent/NZ253138A/en
Priority to CZ943296A priority patent/CZ282235B6/cs
Priority to EP93912990A priority patent/EP0671948B1/en
Priority to UA95018058A priority patent/UA40597C2/uk
Priority to ES93912990T priority patent/ES2108278T3/es
Priority to KR1019940704740A priority patent/KR100278157B1/ko
Priority to DK93912990.4T priority patent/DK0671948T3/da
Priority to US08/356,372 priority patent/US5750110A/en
Priority to PCT/EP1993/001524 priority patent/WO1994000153A1/en
Priority to AT93912990T priority patent/ATE156710T1/de
Priority to DE69327599T priority patent/DE69327599T2/de
Priority to CA002138997A priority patent/CA2138997C/en
Priority to MYPI93001207A priority patent/MY109278A/en
Priority to IL10610993A priority patent/IL106109A/xx
Priority to SI9300335A priority patent/SI9300335B/sl
Priority to MX9303773A priority patent/MX9303773A/es
Priority to MX9303771A priority patent/MX9303771A/es
Priority to MA23212A priority patent/MA22911A1/fr
Priority to CN93109561A priority patent/CN1092812A/zh
Priority to CN93107990A priority patent/CN1122530C/zh
Priority to APAP/P/1993/000541A priority patent/AP408A/en
Priority to TW82107123A priority patent/TW269635B/zh
Priority to SA93140234A priority patent/SA93140234B1/ar
Priority to FI946064A priority patent/FI109767B/fi
Priority to NO19945003A priority patent/NO317546B1/no
Priority to KR1019940704739A priority patent/KR950702244A/ko
Priority to AU17855/97A priority patent/AU1785597A/en
Priority to US08/909,879 priority patent/US7147862B1/en
Priority to GR970402819T priority patent/GR3025184T3/el
Priority to HK98110943A priority patent/HK1010097A1/xx
Priority to HK99105834A priority patent/HK1022074A1/xx
Priority to GR20000400442T priority patent/GR3032742T3/el
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
GB9213559A 1992-06-25 1992-06-25 Vaccines Pending GB9213559D0 (en)

Priority Applications (53)

Application Number Priority Date Filing Date Title
GB9213559A GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines
NZ253137A NZ253137A (en) 1992-06-25 1993-06-15 Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
SG9901248A SG90042A1 (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants
EP19930912991 EP0649470A1 (en) 1992-06-25 1993-06-15 Immediate early hsv-2 viral protein icp27 as vaccine
EP96203085A EP0761231B1 (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants
PCT/EP1993/001525 WO1994000575A1 (en) 1992-06-25 1993-06-15 Immediate early hsv-2 viral protein icp27 as vaccine
RU94046232A RU2118164C1 (ru) 1992-06-25 1993-06-15 Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины
SG1996009012A SG49909A1 (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants
CA 2138996 CA2138996A1 (en) 1992-06-25 1993-06-15 Immediate early hsv-2 viral protein icp27 as vaccine
JP6502006A JPH07508648A (ja) 1992-06-25 1993-06-15 ワクチンとしての即時型ｈｓｖ−２ウイルスタンパク質ｉｃｐ２７
PL93306722A PL170980B1 (pl) 1992-06-25 1993-06-15 Szczepionka PL PL PL PL PL PL PL
DK96203085T DK0761231T3 (da) 1992-06-25 1993-06-15 Vaccinepræparat indeholdende adjuvanser
AT96203085T ATE188613T1 (de) 1992-06-25 1993-06-15 Adjuvantien enthaltende impfstoffzusammensetzung
DE69313134T DE69313134T2 (de) 1992-06-25 1993-06-15 Adjuvantien enthaltende impfstoffzusammensetzung
AU43263/93A AU661404B2 (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants
PT96203085T PT761231E (pt) 1992-06-25 1993-06-15 Composicao de vacina contendo adjuvantes
HU9403778A HU219808B (hu) 1992-06-25 1993-06-15 Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására
AU43264/93A AU676166B2 (en) 1992-06-25 1993-06-15 Immediate early HSV-2 viral protein ICP27 as vaccine
SK1592-94A SK279188B6 (sk) 1992-06-25 1993-06-15 Vakcínová kompozícia spôsob jej prípravy a použiti
ES96203085T ES2143716T3 (es) 1992-06-25 1993-06-15 Composicion de vacuna que contiene adyuvantes.
JP50200594A JP3755890B2 (ja) 1992-06-25 1993-06-15 アジュバント含有ワクチン組成物
NZ253138A NZ253138A (en) 1992-06-25 1993-06-15 Hsv-2 protein icp-27, dna, recombinant production
CZ943296A CZ282235B6 (cs) 1992-06-25 1993-06-15 Očkovací prostředek, jeho použití k výrobě vakcíny, způsob léčby patogenních infekcí tímto prostředkem a způsob jeho výroby
EP93912990A EP0671948B1 (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants
UA95018058A UA40597C2 (uk) 1992-06-25 1993-06-15 Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
ES93912990T ES2108278T3 (es) 1992-06-25 1993-06-15 Composicion de vacuna con coadyuvantes.
KR1019940704740A KR100278157B1 (ko) 1992-06-25 1993-06-15 보조약을 함유하는 백신 조성물
DK93912990.4T DK0671948T3 (da) 1992-06-25 1993-06-15 Vaccinepræparat indeholdende adjuvanser
US08/356,372 US5750110A (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants
PCT/EP1993/001524 WO1994000153A1 (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants
AT93912990T ATE156710T1 (de) 1992-06-25 1993-06-15 Adjuvantien enthaltende impfstoffzusammensetzung
DE69327599T DE69327599T2 (de) 1992-06-25 1993-06-15 Adjuvantien enthaltende Impfstoffzusammensetzung
CA002138997A CA2138997C (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants
MYPI93001207A MY109278A (en) 1992-06-25 1993-06-22 Vaccines
IL10610993A IL106109A (en) 1992-06-25 1993-06-23 Vaccine compositions comprising QS21 and 3D-MPL
SI9300335A SI9300335B (sl) 1992-06-25 1993-06-23 Vakcinski sestavek,ki obsega 3-DE-O-aciliran monofosforni lipid A in QS21
MX9303773A MX9303773A (es) 1992-06-25 1993-06-23 Composicion de vacuna que comprende un antigeno y/o una composicion antigenica de qs21 y monofosforil-lipido a 3-des-o-acilado y proceso para su elaboracion.
MX9303771A MX9303771A (es) 1992-06-25 1993-06-23 Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye.
MA23212A MA22911A1 (fr) 1992-06-25 1993-06-23 Procede de production de formulations de vaccins.
CN93109561A CN1092812A (zh) 1992-06-25 1993-06-24 疫苗
CN93107990A CN1122530C (zh) 1992-06-25 1993-06-24 疫苗
APAP/P/1993/000541A AP408A (en) 1992-06-25 1993-06-24 Vaccine composition containing adjuvants.
TW82107123A TW269635B (xx) 1992-06-25 1993-09-01
SA93140234A SA93140234B1 (ar) 1992-06-25 1993-10-03 تركيبة لقاح تحتوي على مواد مساعدة للمناعة adjuvants
FI946064A FI109767B (fi) 1992-06-25 1994-12-23 Menetelmä rokotekoostumuksen valmistamikseksi
NO19945003A NO317546B1 (no) 1992-06-25 1994-12-23 Vaksineblanding, samt anvendelse og fremgangsmate for fremstilling derav
KR1019940704739A KR950702244A (ko) 1992-06-25 1994-12-24 백신으로서의 즉석 초기 hsv-2 비루스 단백질 icp27(immediatie early hsv-2 viral protein icp27 as vaccine)
AU17855/97A AU1785597A (en) 1992-06-25 1997-04-14 Immediate early HSV-2 viral protein ICP27 as vaccine
US08/909,879 US7147862B1 (en) 1992-06-25 1997-08-12 Vaccine composition containing adjuvants
GR970402819T GR3025184T3 (en) 1992-06-25 1997-10-29 Vaccine composition containing adjuvants.
HK98110943A HK1010097A1 (en) 1992-06-25 1998-09-24 Vaccine composition containing adjuvants
HK99105834A HK1022074A1 (en) 1992-06-25 1998-09-24 Vaccine composition containing adjuvants
GR20000400442T GR3032742T3 (en) 1992-06-25 2000-02-23 Vaccine composition containing adjuvants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9213559A GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines

Publications (1)

Publication Number Publication Date
GB9213559D0 true GB9213559D0 (en) 1992-08-12

Family

ID=10717757

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9213559A Pending GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines

Country Status (11)

Country Link
EP (1) EP0649470A1 (xx)
JP (1) JPH07508648A (xx)
KR (1) KR950702244A (xx)
CN (1) CN1092812A (xx)
AU (2) AU676166B2 (xx)
CA (1) CA2138996A1 (xx)
GB (1) GB9213559D0 (xx)
MX (1) MX9303771A (xx)
NZ (1) NZ253138A (xx)
TW (1) TW269635B (xx)
WO (1) WO1994000575A1 (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1584685E (pt) 1998-02-05 2011-06-17 Glaxosmithkline Biolog Sa Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação
ATE449858T1 (de) * 1999-10-11 2009-12-15 Pasteur Institut Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection

Also Published As

Publication number Publication date
KR950702244A (ko) 1995-06-19
MX9303771A (es) 1994-05-31
AU1785597A (en) 1997-06-19
CA2138996A1 (en) 1994-01-06
AU4326493A (en) 1994-01-24
CN1092812A (zh) 1994-09-28
AU676166B2 (en) 1997-03-06
WO1994000575A1 (en) 1994-01-06
NZ253138A (en) 1995-10-26
EP0649470A1 (en) 1995-04-26
JPH07508648A (ja) 1995-09-28
TW269635B (xx) 1996-02-01

Similar Documents

Publication Publication Date Title
AP9300541A0 (en) Vaccines
AP9300530A0 (en) Vaccines
ZA947828B (en) Vaccines
GB9106048D0 (en) Vaccines
GB9325496D0 (en) Vaccines
GB9215233D0 (en) Vaccines
ZA93919B (en) Vaccines
GB9213559D0 (en) Vaccines
GB9214871D0 (en) Vaccines
GB9201023D0 (en) Vaccines
ZA948685B (en) Vaccines
ZA948729B (en) Vaccines
GB9226768D0 (en) Vaccines
ZA933541B (en) Vaccines
GB9218833D0 (en) Vaccines
ZA935281B (en) Vaccines
GB9211318D0 (en) Vaccines
GB9217635D0 (en) Vaccines
GB9216317D0 (en) Vaccines
GB9220360D0 (en) Vaccines
GB9221891D0 (en) Vaccines
GB9226283D0 (en) Vaccines
GB9206786D0 (en) Vaccine
GB9206788D0 (en) Vaccine
GB9307028D0 (en) Vaccine